Hillmen, P. The Role of Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia (CLL) and the Achievement of Minimal Residual Disease Negativity in relapsed/Refractory CLL. Hematol Meeting Rep 2009, 1.